1. HOME
  2. ABOUT US
    About Laekna Core Management Team Board of Directors Milestones Scientific Advisory Board Core Inverstors Honors & Awards
  3. R&D
    R&D Therapeutic Areas Candidates Pipeline Clinical Trials
  4. PARTNERSHIPS
    Strategic Partners Business Development Holistic Approach BD Contact
  5. INVESTORS
    Corporate Governance Financial Results Announcements and Circulars IR Calendar Listing Documents
  6. NEWS
    Press Releases Media Coverage
  7. CAREERS
    Global Team Career Development Jobs My Laekna
  8. CONTACT US
    Contact Us Leave Message
  9. RSS Feeds
 ABOUT US
GROUND-BREAKING THERAPEUTICS

Founded in 2016,

we are a clinical-stage biotechnology company

Learn More
Operation Team
Research & Development Team
in China and the US
 ABOUT US
GROUND-BREAKING THERAPEUTICS

Founded in 2016,

we are a clinical-stage biotechnology company

Learn More
Research & Development Team
in China and the US
Zhangjiang Pharma Valley, Shanghai, China
New Jersey, USA
Operation Team
Lingang, Shanghai
R&D
LEADING INNOVATION

Committed to bringing

novel therapies to

cancer and liver fibrosis patients worldwide


More in the pipeline

  1. 16

    innovative product

    candidates

  2. 6

    clinical

    trials

  3. including3

    multi-regional clinical trials

    (MRCTs)

  4. including1

    pivotal

    clinical trial

  5. 176

    patents and

    patent applications

NEWS
LATEST ARTICLES
Learn More
  1. 2023-11-20
    Dr. Yong YUE, CMO of Laekna, Will Attend the SABCS 2023 and Announce the Phase Ib Study Data of Afuresertib in Breast Cancer
    More
  2. 2023-11-02
    Laekna Announces Two Poster Presentations on New Preclinical Bispecific Antibody Data at SITC 2023
    More
  3. 2023-10-24
    2023 ESMO│Laekna (2105.HK) Announces Phase I/II Data of LAE001 plus afuresertib in mCRPC
    Learn More
    2023-09-22
    Laekna Announces New Afuresertib Clinical Data in Breast Cancer to Be Presented at SABCS 2023
    Learn More
NEWS
LATEST ARTICLES
Learn More
  1. 2023-11-20
    Dr. Yong YUE, CMO of Laekna, Will Attend the SABCS 2023 and Announce the Phase Ib Study Data of Afuresertib in Breast Cancer
    More
  2. 2023-11-02
    Laekna Announces Two Poster Presentations on New Preclinical Bispecific Antibody Data at SITC 2023
    More
  3. 2023-10-24
    2023 ESMO│Laekna (2105.HK) Announces Phase I/II Data of LAE001 plus afuresertib in mCRPC
    More
CAREERS
OUR PEOPLE
Join Us
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin

  1. HOME
  2. ABOUT US
  3. R&D
  4. PARTNERSHIPS
  5. INVESTORS
  6. INVESTORS
  7. NEWS
  8. CAREERS

Copyright © Laekna Therapeutics, All Rights Reserved.  Privacy Policy

Follow us on Linkedin

Follow us on Wechat